Ozempic’s Surge and the Cost Crisis | Washington DC News

Ozempic’s skyrocketing popularity—up 643% between 2017 and 2022—isn’t just a diabetes win; it’s a weight-loss phenomenon driving up drug costs and putting pressure on insurers and government programs. While users pay less out of pocket, total expenses are climbing, risking higher premiums for everyone. These GLP-1 drugs, originally for blood sugar control, are now a double-edged sword: powerful for health but financially destabilizing. Experts are racing to find policies that keep them affordable and accessible without breaking the system. Thank you to our sponsor Garrett Waller Performance: http://coaching.garrettwaller.com Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/861fb7dea50f7367